Chi Zhang

机构：Mayo Clinic, Army Medical University, Sun Yat-sen University, Xuzhou Medical College, Fudan University, WinnMed, Third Affiliated Hospital of Guangzhou Medical University, Daping Hospital, Sixth Affiliated Hospital of Sun Yat-sen University, Zhejiang Lab, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital of Henan University of Science and Technology, Northern Jiangsu People's Hospital, Jiangsu Hengrui Medicine (China), Guangzhou Medical University · ORCID：0000-0002-4826-7877

发表论文 78 篇 · 总被引 943 次 · h-index 17

代表论文

• NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer (2025 · International Immunopharmacology · 被引 33)
• SKP alleviates the ferroptosis in diabetic kidney disease through suppression of HIF-1α/HO-1 pathway based on network pharmacology analysis and experimental validation (2024 · Chinese Medicine · 被引 21)
• Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy (2024 · Journal of Medicinal Chemistry · 被引 16)
• Effects of Indocyanine Green (ICG) Imaging-Assisted Cholecystectomy on Intraoperative and Postoperative Complications: A meta-Analysis (2024 · Surgical Innovation · 被引 12)
• A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer (2024 · Journal of Cancer Research and Clinical Oncology · 被引 9)
• LTBK-09. RESULTS OF BMX-HGG STUDY: A MULTI-INSTITUTIONAL, RANDOMIZED PHASE 2 CLINICAL TRIAL OF CONCURRENT CHEMORADIATION WITH OR WITHOUT BMX-001 IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMA (2023 · Neuro-Oncology · 被引 9)